Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Integrin alpha 7 correlates with poor clinical outcomes, and it regulates cell proliferation, apoptosis and stemness via PTK2-PI3K-Akt signaling pathway in hepatocellular carcinoma.
|
31698037 |
2020 |
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Circ_0015756 knockdown was shown to increase the expression of miR-7, reduce the proliferation, invasion, migration and resistance to apoptosis, and down-regulate the expression of FAK in HCC.
|
31522588 |
2019 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The present data suggest that PTK2 may be a novel prognostic biomarker for HCC recurrence, and a therapeutic target for HCC treatment.
|
30849480 |
2019 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
BI-3663 (cereblon-based) degrades PTK2 with a median DC<sub>50</sub> of 30 nM to >80% across a panel of 11 HCC cell lines.
|
30739444 |
2019 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Additionally, high expression of both cPLA2α and p-FAK predicted the worst prognoses for HCC patients.
|
31516757 |
2019 |
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Taken together, our data demonstrate a novel function of LOXL4 in tumor metastasis mediated by exosomes through regulation of the FAK/Src pathway and angiogenesis in HCC.
|
30704479 |
2019 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The focal adhesion kinase (FAK) gene protein tyrosine kinase 2 is amplified in 16.4% of The Cancer Genome Atlas HCC specimens, and its amplification leads to increased FAK mRNA expression.
|
31069844 |
2019 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Inhibition of SRC/FAK cue: A novel pathway for the synergistic effect of rosuvastatin on the anti-cancer effect of dasatinib in hepatocellular carcinoma.
|
30292831 |
2018 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
DBH-AS1 facilitated the development of HCC via miR-138/FAK/Src/ERK pathway, establishing the molecular basis of DBH-AS1 in clinical application for HCC.
|
30142544 |
2018 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
CD31 regulates metastasis by inducing epithelial-mesenchymal transition in hepatocellular carcinoma via the ITGB1-FAK-Akt signaling pathway.
|
29746931 |
2018 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Mitochondrial fission promotes cell migration by Ca<sup>2+</sup> /CaMKII/ERK/FAK pathway in hepatocellular carcinoma.
|
29210177 |
2018 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Interestingly, western blot analysis showed that treatment with oxaliplatin increased GAS7C and N-WASP protein levels and decreased the levels of proteins involved in the fibronectin/integrin/FAK pathway, such as FAK, in both HCC cell lines.
|
28475688 |
2017 |
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, Rab5a is overexpressed in human HCC and contributes to cancer cell proliferation and invasion through regulation of FAK and AKT signaling.
|
26443539 |
2016 |
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Moreover, the expression levels of beta-catenin, cyclin D1, c-Myc, MMP-2, and FAK detected by western blotting were downregulated in SLC5A8-transfected HCC cells compared with control-transfected cells, indicating that SLC5A8 has a tumor-suppressive function that acts by interfering with Wnt/β-catenin signaling in HCC.
|
27465549 |
2016 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
MACC1 or combination of MACC1/FAK could serve as a novel biomarker in predicting the prognosis of HCC after LT.
|
24516351 |
2014 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
It was also shown that the combination of SKI II and U0126 further attenuated the migration of hepatoma HepG2 cells via FAK/MLC-2 signaling pathway.
|
23545258 |
2013 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In addition, miR-151 can function synergistically with FAK to enhance HCC cell motility and spreading.
|
20305651 |
2010 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
LHGDN |
Focal adhesion kinase: important to prostaglandin E2-mediated adhesion, migration and invasion in hepatocellular carcinoma cells.
|
19082453 |
2009 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
RGD |
Marked suppression of tumor growth by FTY720 in a rat liver tumor model: the significance of down-regulation of cell survival Akt pathway.
|
17203219 |
2007 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
LHGDN |
We also found that SOCS-3 physically interacted with phosphorylated FAK and Elongin B in HCC cells.
|
16007195 |
2005 |
Liver carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We also found that the phosphorylation levels of FAK in both of the hepatoma cell lines were higher than that in L02 hepatic cells.
|
15532706 |
2004 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
LHGDN |
FAK proteins were detected in all HCC cell lines.
|
15102689 |
2004 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In conclusion, PTK2 and EIF3S3, which, respectively, encode focal adhesion kinase and the p40 subunit of the eukaryotic initiation factor 3, were probable targets within the amplification at 8q23-q24 and may be involved in progression of HCC.
|
14578863 |
2003 |
Liver carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
In conclusion, PTK2 and EIF3S3, which, respectively, encode focal adhesion kinase and the p40 subunit of the eukaryotic initiation factor 3, were probable targets within the amplification at 8q23-q24 and may be involved in progression of HCC.
|
14578863 |
2003 |
Glioblastoma Multiforme
|
0.550 |
Biomarker
|
disease |
BEFREE |
A recent study showed that a combination of Y15 (a FAK autophosphorylation inhibitor) with temozolomide (TMZ) treatment was effective in glioblastoma (GBM) therapy.
|
31360198 |
2019 |